

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/058571 A1

(51) International Patent Classification:

A61K 39/385 (2006.01) *C07K 16/42* (2006.01)
A61K 39/00 (2006.01) *A61K 38/17* (2006.01)
A61P 37/08 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:

PCT/EP2021/075732

(22) International Filing Date:

17 September 2021 (17.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20306047.0 17 September 2020 (17.09.2020) EP
63/079,686 17 September 2020 (17.09.2020) US

(71) Applicants: **NEOVACS** [FR/FR]; 3-5 impasse Reille,
75014 Paris (FR). **INSERM (INSTITUT NATIONAL DE
LA SANTÉ ET DE LA RECHERCHE MÉDICALE)**
[FR/FR]; 101 rue de Tolbiac, 75013 Paris (FR). **INSTITUT
PASTEUR** [FR/FR]; 25-28 rue du Docteur Roux, 75015
Paris (FR).

(72) Inventors: **REBER, Laurent**; 7, rue Jean Campistron,
31170 Tournefeuille (FR). **BRUHNS, Pierre**; INSERM
Unit 1222, Department of Immunology, Institut Pasteur,
25, rue du Dr Roux, 75015 Paris (FR). **CONDE GAR-
CIA, Eva**; INSERM Unit 1222, Department of Immunolo-
gy, Institut Pasteur, 25, rue du Dr Roux, 75015 Paris (FR).
BACKOVIC, Marija; Unité de Virologie Structurale, Dé-
partement de Virologie, Institut Pasteur, 28, rue du Dr Roux,
75015 Paris (FR). **SERRA, Vincent**; 8 place de l'Église,
91070 Bondoufle (FR). **GROUARD-VOGEL, Géraldine**;
15, rue Sarrette, 75014 Paris (FR). **BERTRAND, Romain**;
Köchlstrasse 14, 8004 ZÜRICH (CH).

(74) Agent: **ICOSA**; 83 avenue Denfert-Rochereau, 75014 Paris
(FR).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMA-
TORY DISORDERS

(57) Abstract: The present invention relates to an immunogenic product comprising at least one immunoglobulin or fragment thereof
conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment comprises
the IgE Cε3 domain, and wherein the carrier protein is preferably CRM197. The present invention further relates to the use of said
immunogenic product for treating inflammatory disorders, and in particular allergic disorders.

WO 2022/058571 A1